Could patients taking isotretinoin therapy be immune against
            <scp>SARS‐CoV</scp>
            ‐2?

Elgarhy, Lamia Hamouda

doi:10.1111/dth.13573

Cited by 9 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been documented that isotretinoin is a protease inhibitors and can be a taken as a target therapy in COVID-19 (42). After our clinical trial many studies con rmed our suggestion and found that isotretinoin and all trans retinoic acid could protect individuals against COVID-19 complication (43,44,45,46,47,48).…”

Section: I) Part Of Covid-19supporting

confidence: 58%

Utilizing the Crosstalk Among Minocycline, Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized) and Vitamin D as a Potent Quadrate Therapy for treating coinfection with Multidrug-resistant TB and COVID-19 . A double-edged sword Clinical Study

Elkazzaz

Ahmed²

2021

Preprint

View full text Add to dashboard Cite

Tuberculosis (TB) is a major infectious disease killer globally. It affected 10 million and killed 1.4 million people in 2019 alone. TB is considered a disease caused by a bacterium—Mycobacterium tuberculosis—that usually attacks the lungs, but can attack any part of the body. But TB has a worrisome connection to the novel coronavirus.. Both diseases are airborne and spread when people cough or sneeze. The predicted impact of the COVID-19 pandemic is an additional 190,000 TB deaths in 2020, and it is expected in the next 5 y that there will be up to a 20% increase in the global TB disease burden, stressing the critical need for new safe and effective drugs against Mycobacterium tuberculosis (Mtb). In addition, controlling multidrug-resistant TB (MDR-TB) presents a huge public health challenge. Recently it was showed that hospitalized patients with Tuberculosis are more susceptible to COVID-19 infection and complication. Furthermore, hospitalized patients with MDR-TB are increasingly vulnerable to COVID-19 complications than patients with non-resistant tuberculosis.. For someone with latent TB, contracting COVID-19 could activate the bacterium, potentially leading to an accelerated and more severe form of the disease WHO estimates that these COVID-19 related disruptions in access to TB care could cause an additional half a million TB deaths. Older age, especially >65 years, may be a risk factor for death from COVID-TB, consistent with previous findings indicating that the mortality rate from COVID-19 increases exponentially with age. Thus, the elderly should be the primary focus of both COVID-19 and COVID-TB mitigation efforts due to its much higher mortality risk in that group. COVID-TB patients had a much higher rate of comorbidities than COVID-19 patients At present, evidence suggests that the main transmission route of both COVID-19 and TB is via respiratory droplets, and their main target are the lungs, which can lead to a worse outcome among COVID-19 and TB coinfection patients (aptly abbreviated COVID-TB). As a result, coinfections with common viral and bacterial (COVID-TB) pathogens among hospitalized patients are a severe concern that will likely worsen patient outcomes and pose a real challenge for treating those patients.ConclusionsNew drug discovery could require several years with no guarantee but repurposing established drugs may be useful to treat confection with COVID-19 and Nonresistant Strains of Mycobacterium tuberculosis: or resistant Strains of Mycobacterium tuberculosis . Here we demonstrate that we could utilize the crosstalk among Chicoric Acid, 13-Cis Retinoic Acid, Minocycline and vitamin D as a novel quadrate therapy against Multidrug-resistant TB and COVID-19 coinfection.

show abstract

Section: I) Part Of Covid-19supporting

confidence: 58%

Utilizing the Crosstalk Among Minocycline, Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized) and Vitamin D as a Potent Quadrate Therapy for treating coinfection with Multidrug-resistant TB and COVID-19 . A double-edged sword Clinical Study

Elkazzaz

Ahmed²

2021

Preprint

View full text Add to dashboard Cite

show abstract

“… 16 On the other hand, it has been claimed that the use of isotretinoin might prevent the cellular entry of SARS‐CoV‐2, since isotretinoin is one of the strongest down‐regulator of ACE‐2 receptors. Moreover, immunomodulatory effects of isotretinoin through inhibition of papain‐like protease, encoded by SARS‐CoV‐2 and a potential target protein in the treatment of COVID‐19, 17 might lower risk of getting COVID‐19 in patients with acne vulgaris 18 . These reports were only comments on the possible effect of isotretinoin on COVID‐19 mostly based on in vitro studies, 17,19 and not supported by real‐world experiences with clinical studies.…”

Section: Discussionmentioning

confidence: 99%

“…16 On the other hand, it has been claimed that the use of isotretinoin might prevent the cellular entry of SARS- COVID-19, 17 might lower risk of getting COVID-19 in patients with acne vulgaris. 18 These reports were only comments on the possible effect of isotretinoin on COVID-19 mostly based on in vitro studies, 17,19 and not supported by real-world experiences with clinical studies.…”

Section: Ta B L E 1 Demographics and Clinical Characteristics Of The ...mentioning

confidence: 99%

Oral isotretinoin treatment in patients with acne vulgaris during the COVID‐19 pandemic: A retrospective cohort study in a tertiary care hospital

Öğüt

Kutlu

Erbağcı

2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background: Patients with acne vulgaris continue to present increasingly in dermatology outpatient clinics and seek treatment during the COVID-19 pandemic. As far as we know, the effect of isotretinoin on COVID-19 has not been studied before. Aim:We aimed to evaluate whether patients receiving oral isotretinoin are at increased risk of COVID-19 infection by comparing them with patients on topical treatment for acne vulgaris. Methods:The data were collected retrospectively from a cohort of 267 acne vulgaris patients, who were under follow-up for acne vulgaris treatment during the pandemic period.

show abstract

“…The rationale behind investigating isotretinoin as a candidate for drug repurposing against COVID-19 resides in the following four properties of the drug: (1) modulation of IL-2, interferon γ (IFN-γ) and T and B lymphocyte function, 149 (2) down regulation of ACE2 receptors, 157 which are essential for the viral entry into the host cell, 158 (3) potential inhibition of papain-like protease (PLpro)-protein encoded by SARS-CoV-2 genes, 159 and (4) increase of CD4 counts and marked decrease of viremia in HIV-positive patients. 160 …”

Section: Repurposing Of Dermatologic Medications To Treat Covid-19mentioning

confidence: 99%

Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?

Mateeva

Drenovska

2021

Clinics in Dermatology

View full text Add to dashboard Cite

No pharmaceutical products have been demonstrated to be safe and effective to specifically treat coronavirus disease 2019 (COVID-19); therefore, the therapy administered to infected patients remains symptomatic and empiric. Alongside the development of new, often high-cost drugs, a different tactic is being applied in parallel, investigating long-established, inexpensive medications originally designed for a variety of diseases to study their potential in treating COVID-19. The skin is the largest organ of the human body. With more than 3,000 skin conditions identified, the specialty of dermatology offers a rich armamentarium of systemic therapeutic agents aimed to treat the various chronic immunologically mediated, metabolic, infectious, occupational, inherited, or paraneoplastic dermatoses. Dermatologists have extensive experience with many drugs that have demonstrated promising in vitro antiviral action (directly targeting the viral replication). Many of these drugs have been used as nonspecific immunosuppressive strategies, such as glucocorticoids, synthetic antimalarials, colchicine, or other immunomodulators, and a number of targeted therapeutics have been directed at controlling hyperinflammatory processes similar to the “cytokine storm” associated with COVID-19 infection. We discuss several dermatologic drugs that have already been used or may have a promising role in the treatment of COVID-19.

show abstract

Could patients taking isotretinoin therapy be immune against SARS‐CoV ‐2?

Cited by 9 publications

References 6 publications

Utilizing the Crosstalk Among Minocycline, Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized) and Vitamin D as a Potent Quadrate Therapy for treating coinfection with Multidrug-resistant TB and COVID-19 . A double-edged sword Clinical Study

Utilizing the Crosstalk Among Minocycline, Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized) and Vitamin D as a Potent Quadrate Therapy for treating coinfection with Multidrug-resistant TB and COVID-19 . A double-edged sword Clinical Study

Oral isotretinoin treatment in patients with acne vulgaris during the COVID‐19 pandemic: A retrospective cohort study in a tertiary care hospital

Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?

Contact Info

Product

Resources

About